201 related articles for article (PubMed ID: 21465129)
1. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series.
Deal EN; Hollands JM; Riney JN; Skrupky LP; Smith JR; Reichley RM
J Thromb Thrombolysis; 2011 Aug; 32(2):188-94. PubMed ID: 21465129
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
3. Assessing an enoxaparin dosing protocol in morbidly obese patients.
Lalama JT; Feeney ME; Vandiver JW; Beavers KD; Walter LN; McClintic JR
J Thromb Thrombolysis; 2015 May; 39(4):516-21. PubMed ID: 25087072
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
5. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
May CC; Cua S; Smetana KS; Powers CJ
World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
Freeman A; Horner T; Pendleton RC; Rondina MT
Am J Hematol; 2012 Jul; 87(7):740-3. PubMed ID: 22565589
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Treatment-Dose Enoxaparin in Acutely Ill Morbidly Obese Patients at an Academic Medical Center: A Randomized Clinical Trial.
Curry MA; LaFollette JA; Alexander BR; Evans KS; Tran RH; Kempton CL
Ann Pharmacother; 2019 Jun; 53(6):567-573. PubMed ID: 30574790
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
9. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
10. Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.
Lee YR; Palmere PJ; Burton CE; Benavides TM
Clin Drug Investig; 2020 Jan; 40(1):33-40. PubMed ID: 31625111
[TBL] [Abstract][Full Text] [Related]
11. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.
Simone EP; Madan AK; Tichansky DS; Kuhl DA; Lee MD
Surg Endosc; 2008 Nov; 22(11):2392-5. PubMed ID: 18594915
[TBL] [Abstract][Full Text] [Related]
13. Comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboprophylaxis in patients undergoing bariatric surgery: A randomized controlled trial.
Kongsawat K; Chaivanijchaya K; Pakul F; Joradol S; Kachornvitaya P; Boonchaya-Anant P; Udomsawaengsup S
Asian J Surg; 2024 Jul; 47(7):2985-2990. PubMed ID: 38514281
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin dosing after cesarean delivery in morbidly obese women.
Overcash RT; Somers AT; LaCoursiere DY
Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
[TBL] [Abstract][Full Text] [Related]
15. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
16. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Taylor A; Huang E; Waller J; White C; Martinez-Quinones P; Robinson T
Pharmacotherapy; 2021 Jun; 41(6):508-514. PubMed ID: 33864688
[TBL] [Abstract][Full Text] [Related]
17. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.
Rondina MT; Wheeler M; Rodgers GM; Draper L; Pendleton RC
Thromb Res; 2010 Mar; 125(3):220-3. PubMed ID: 19272635
[TBL] [Abstract][Full Text] [Related]
18. Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis.
Pannucci CJ; Hunt MM; Fleming KI; Prazak AM
Plast Reconstr Surg; 2017 Oct; 140(4):815-822. PubMed ID: 28953735
[TBL] [Abstract][Full Text] [Related]
19. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients.
Bigos R; Solomon E; Dorfman JD; Ha M
J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
